In Re: Modafinil AntiTrust v.

Court of Appeals for the Third Circuit·Decided September 29, 2016·No. 15-3475·Published

Opinion

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

No. 15-3475

IN RE: MODAFINIL ANTITRUST LITIGATION

Mylan Laboratories, Inc.; Mylan Pharmaceuticals Inc.; Ranbaxy Laboratories, Ltd; Ranbaxy Pharmaceuticals, Inc., Appellants

On Appeal from the United States District Court for the Eastern District of Pennsylvania District Court No. 2-06-cv-01797 District Judge: The Honorable Mitchell S. Goldberg

Before: SMITH, JORDAN, and RENDELL, Circuit Judges

ORDER AMENDING OPINION

The opinion filed September 13, 2016 is amended solely as to the listing of Paul

B. Hewitt, Esq. and Catherine Creely, Esq. on the opinion and not as to the substance of

the opinion itself. Mr. Hewitt and Ms. Creely should have been listed as members of

Akin Gump Strauss Hauer & Feld in Washington, DC. Mr. Hewitt was omitted from the

listing of counsel and Ms. Creely was erroneously listed as a member of Cohn & Marks

in Washington, DC. The opinion is amended as follows:

Paul B. Hewitt C. Fairley Spillman Catherine E. Creely Akin Gump Strauss Hauer & Feld 1333 New Hampshire Avenue, N.W. Suite 400 Washington, DC 20036

For the Court,

Marcia M. Waldron, Clerk Date: September 29, 2016 PDB/cc: All Counsel of Record

Free access — add to your briefcase to read the full text and ask questions with AI

In Re: Modafinil AntiTrust v., (3d Cir. 2016).

In Re: Modafinil AntiTrust v. (In Re: Modafinil AntiTrust v.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.